Bristol Company Profile

BRISTOL has one hundred and nineteen approved drugs.

There are seventy-seven US patents protecting BRISTOL drugs.

US Patents:	77
Tradenames:	96
Ingredients:	84
NDAs:	119
Patent Litigation for Bristol:	See patent lawsuits for Bristol
PTAB Cases with Bristol as patent owner:	See PTAB cases with Bristol as patent owner

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	STILBESTROL	diethylstilbestrol	INJECTABLE;INJECTION	004056-005	Approved Prior to Jan 1, 1982		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
Bristol	POMALYST	pomalidomide	CAPSULE;ORAL	204026-002	Feb 8, 2013	AB	RX	Yes	No	9,993,467*PED	⤷ Start Trial			Y	⤷ Start Trial
Bristol Myers Squibb	COUMADIN	warfarin sodium	INJECTABLE;INJECTION	009218-024	Feb 7, 1995		DISCN	No	No		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-003	Jan 17, 2003	7,874,984	⤷ Start Trial
Bristol-myers	THALOMID	thalidomide	CAPSULE;ORAL	020785-004	Jan 10, 2007	6,908,432	⤷ Start Trial
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-002	Dec 27, 2005	8,626,531	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Capsules	150 mg	➤ Subscribe	2014-02-03
➤ Subscribe	Capsules	2.5 mg and 20 mg	➤ Subscribe	2016-07-12
➤ Subscribe	Injection	10 mg/vial	➤ Subscribe	2013-11-05
➤ Subscribe	Capsules	100 mg and 150 mg	➤ Subscribe	2010-03-19
➤ Subscribe	Tablets	600 mg	➤ Subscribe	2009-04-09
➤ Subscribe	Nasal Spray	4 mg/spray	➤ Subscribe	2016-07-15
➤ Subscribe	Tablets	2.5 mg and 5 mg	➤ Subscribe	2016-12-28
➤ Subscribe	Tablets	20 mg, 50 mg, 70 mg and 100 mg	➤ Subscribe	2010-06-28
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-17
➤ Subscribe	Delayed-release Capsules	200 mg, 250 mg and 400 mg	➤ Subscribe	2004-06-01
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2006-09-25
➤ Subscribe	Capsules	5 mg, 10 mg and 15 mg	➤ Subscribe	2010-08-30
➤ Subscribe	For Injection Suspension	100 mg/vial	➤ Subscribe	2015-12-11
➤ Subscribe	Capsules	300 mg	➤ Subscribe	2009-07-20
➤ Subscribe	Capsules	200 mg	➤ Subscribe	2010-02-16
➤ Subscribe	Capsules	50 mg, 100 mg and 200 mg	➤ Subscribe	2016-11-03
➤ Subscribe	Tablets	0.5 mg and 1 mg	➤ Subscribe	2010-06-14
➤ Subscribe	Tablets	30 mg	➤ Subscribe	2005-06-01
➤ Subscribe	Tablets	80 mg and 140 mg	➤ Subscribe	2011-06-16
➤ Subscribe	Capsules	1 mg, 2 mg, 3 mg and 4 mg	➤ Subscribe	2017-02-08
➤ Subscribe	Capsules	50 mg and 100 mg	➤ Subscribe	2006-12-18
➤ Subscribe	Capsules	25 mg	➤ Subscribe	2010-07-12

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1951684	C20210010 00394	Estonia	⤷ Start Trial	PRODUCT NAME: FEDRATINIIB;REG NO/DATE: EU/1/20/1514; 09.02.2021
2049506	CA 2015 00060	Denmark	⤷ Start Trial	PRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527
2782584	122021000080	Germany	⤷ Start Trial	PRODUCT NAME: ZUSAMMENSETZUNG, DIE SOWOHL ESTRADIOL (17SS-ESTRADIOL), GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, HYDRATS ODER SOLVATS DAVON (EINSCHLIESSLICH IN FORM EINES HEMIHYDRATS), ALS AUCH PROGESTERON ENTHAELT; AUTHORISATION NO/DATE: 2205034.00.00 20210924; BE582231 20210406
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.